Pretraga
Rezultati
Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
[2016]
Bila, Jelena Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy
[2017]
Ćojbašić, Irena Treating Multiple Myeloma: 10 Years of Experience at the National Cancer Research Center of Serbia [2025]
Kojic, Andrijana; Puric, MilaPrognostic Effect of Comorbidity Indices in Elderly Patients With Multiple Myeloma
[2015]
Bila, Jelena Assessment of Symptom Burden Among Patients Diagnosed with Multiple Myeloma (MM) Admitted to Receive Chemotherapy at the Institute for Oncology and Radiology of Serbia (IORS) [2018]
Djordjevic, Fedja RLighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy
[2023]
Mateos, Maria-Victoria; Szarejko, Monika; Bila, Jelena S.
Thuresson, Marcus; Norin, Stefan; Jarefors, Sara; Richardson, Paul; Pour, Ludek;
The second revision of international staging system (R2-ISS) in newly diagnosed multiple myeloma patients: RWE settings
[2023]
Sretenović, Aleksandra M.; Mitrović, Marko; Vukosavljević, Nikola; Kecman, Natalija; Jovanović, Jelica V.; Bukumirić, Zoran M. Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up
[2019]
Ćojbašić, Irena Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group
[2025]
Fotiou, Despina; ...; Bila, Jelena S. Ultra-high-risk prognostic significance of double and triple hit myeloma
[2021]
Bila, Jelena S. Filteri
Po tipu
- 20